Select Page

Another drug gets into trouble. What’s the worry? Well, ask yourself. Do you want a drug that causes immune responses to your own endogenous proteins? We thought not. Read on:

Novo Nordisk scuttles late-stage hemophilia drug over patient risk
September 28, 2012 | By Ryan McBride Fierce Biotech

Danish drugmaker Novo Nordisk ($NVO) has killed development of a hemophilia med once hailed as a successor to its blockbuster product for the bleeding disorder, after the company discovered anti-drug antibodies to the experimental factor VIIa therapy in some study patients, Reuters reported. The setback hampers the company’s work on building its hemophilia franchise as competitors such as Biogen Idec ($BIIB) seek entry to or growth in the market.  . . .  (read more here).